Copertina

Letter: A Prospective Study on the Prevalence of MASLD in Patients With Type 2 Diabetes and Hyperferritinaemia

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Xiaojuan Liu, Xueru Huang, Mingsi Zhang, Tao Jiang, Guangji Zhang
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	Alimentary Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

A Prospective Study on the Prevalence of MASLD in Patients With Type 2 Diabetes and Hyperferritinaemia
di: Maral Amangurbanova, et al.
Pubblicazione: (2024)

Editorial: Hyperferritinaemia—An Ironclad Biomarker for the Prognostication of MASLD?
di: Mark C. C. Cheah, et al.
Pubblicazione: (2025)

Editorial: Evaluating the Prevalence of Metabolic Dysfunction‐Associated Steatotic Liver Disease in Patients With Type 2 Diabetes and Hyperferritinaemia—Authors' Reply
di: Maral Amangurbanova, et al.
Pubblicazione: (2024)

Letter: Bisphosphonate effectiveness in patients with cirrhosis—An emulated clinical trial
di: Mingsi Zhang, et al.
Pubblicazione: (2024)

Letter on ‘Head‐to‐Head Comparison Between Phosphatidylethanol Versus Indirect Alcohol Biomarkers for Diagnosis of MetALD Versus MASLD: A Prospective Study’
di: Muhammad Abubakr, et al.
Pubblicazione: (2025)

Prevalence of Low FIB‐4 in MASLD‐Related Hepatocellular Carcinoma: A Multicentre Study
di: Darren Jun Hao Tan, et al.
Pubblicazione: (2024)

Letter: Lubiprostone—A Novel Therapeutic Avenue for Gastrointestinal Complications in MASLD
di: Hassan Javed, et al.
Pubblicazione: (2025)

Letter: Lubiprostone Treatment for MASLD—Gender Imbalance and Blinding Considerations
di: Jiru Li, et al.
Pubblicazione: (2025)

Letter: Lubiprostone Treatment for MASLD—Gender Imbalance and Blinding Considerations. Authors' Reply
di: Mohamed El‐Kassas, et al.
Pubblicazione: (2025)

Global Longitudinal Assessment of MASLD Using Magnetic Resonance Elastography ( GOLDMINE ): A Multi‐Center, International Prospective Cohort Study of Imaging Biomarkers in MASLD Clinical Outcomes
di: Suzanne Sharpton, et al.
Pubblicazione: (2026)

Letter: Meta‐Analysis: Prevalence of Frailty and Associated Adverse Events in Inflammatory Bowel Disease
di: Cong Dai, et al.
Pubblicazione: (2024)

Letter: MASLD in people with HIV exhibits higher fibrosis stage despite lower disease activity than in matched controls
di: Junbin Yan, et al.
Pubblicazione: (2024)

Letter: Towards Better Intervention Strategies for MASLD and MetALD—What Are We Missing?
di: Qiang Hu, et al.
Pubblicazione: (2024)

Letter: Algorithmic NIT approaches to identify advanced liver fibrosis in patients with MASLD: Authors' reply
di: Stuart McPherson, et al.
Pubblicazione: (2024)

Letter: Clarifying the Synergistic Mechanisms of Mediterranean Diet and Time‐Restricted Feeding in MASLD Management—Authors' Reply
di: Sofia Tsitsou, et al.
Pubblicazione: (2025)

Letter: Towards Better Intervention Strategies for MASLD and MetALD—What Are We Missing? Authors' Reply
di: Yewan Park, et al.
Pubblicazione: (2024)

Head‐to‐Head Comparison Between Phosphatidylethanol Versus Indirect Alcohol Biomarkers for Diagnosis of MetALD Versus MASLD: A Prospective Study
di: Federica Tavaglione, et al.
Pubblicazione: (2025)

Letter: Increased Prevalence of Visceral Obesity in Nonresponder Patients With Primary Biliary Cholangitis Based on Computed Tomography
di: Bo Li, et al.
Pubblicazione: (2024)

Letter: Prospective Individualised Validation of the GES in Predicting Hepatocellular Carcinoma—A ‘Precision Medicine’ Study
di: Ahmed Helmy
Pubblicazione: (2025)

Prevalence and prognosis of patients with MASLD ‐related cirrhosis after an ICU hospitalization in France: A single‐centre prospective study
di: Philippe Sultanik, et al.
Pubblicazione: (2024)

Letter: Using non‐invasive fibrosis tests and emerging diagnostics to enhance the accuracy of liver fibrosis staging in MASLD patients
di: Wenjun Meng, et al.
Pubblicazione: (2024)

Volatomics for Diagnosis and Risk Stratification of MASLD: A Proof‐Of‐Concept Study
di: R. Sinha, et al.
Pubblicazione: (2025)

Editorial: Cardiometabolic criteria matters inMASLD
di: Margaret L. P. Teng, et al.
Pubblicazione: (2024)

Editorial: Polypharmacy in MASLD—An Overlooked Epidemic Disproportionately Affecting Women and Patients With Cirrhosis
di: Mary Yue Wang, et al.
Pubblicazione: (2025)

Letter: Increased Prevalence of Visceral Obesity in Nonresponder Patients With Primary Biliary Cholangitis Based on Computed Tomography—Authors' Reply
di: Conrado Fernandez‐Rodriguez, et al.
Pubblicazione: (2024)

Letter: Impact of antiviral treatment on renal function in patients with chronic hepatitis B
di: Jian Wang, et al.
Pubblicazione: (2024)

Lubiprostone Reduces Fat Content on MRI‐PDFF in Patients With MASLD: A 48‐Week Randomised Controlled Trial
di: Mohamed El‐Kassas, et al.
Pubblicazione: (2025)

Letter: Prospective Individualised Validation of the GES in Predicting Hepatocellular Carcinoma—A ‘Precision Medicine’ Study: Authors' Reply
di: Gamal Shiha, et al.
Pubblicazione: (2025)

Risk of Incident Type 2 Diabetes and Prediabetes in Patients With Direct Acting Antiviral‐Induced Cure of Hepatitis C Virus Infection
di: Yu‐Ping Chang, et al.
Pubblicazione: (2025)

Steatotic Liver Disease Prevalence in China: A Population‐Based Study and Meta‐Analysis of 17.4 Million Individuals
di: Zhenqiu Liu, et al.
Pubblicazione: (2025)

Letter on ‘Inherited Genetic Risk of Liver Fibrosis in Lean Versus Nonlean Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD )’; Authors’ reply
di: Kaleb Tesfai, et al.
Pubblicazione: (2026)

The Magnitude of Polypharmacy and Role of Disease Severity and Patient Sex in Medication Use Among Patients With MASLD Enrolled in TARGET‐NASH
di: Brent A. Neuschwander‐Tetri, et al.
Pubblicazione: (2025)

Letter: Comparison of the Efficacy of Adjuvant PD‐1 Inhibitor After Curative Resection for Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) Related HCC Versus Other Aetiologies
di: Jia‐Yong Su, et al.
Pubblicazione: (2025)

Editorial: Refining the Natural History of MASLD by Imaging‐Based Markers: The GOLDMINE Study
di: Federico Perna, et al.
Pubblicazione: (2026)

Letter: The Risk and Outcomes of Gastrointestinal Bleeding in Patients Using Warfarin or Direct Oral Anticoagulants
di: Jiaqi Shen, et al.
Pubblicazione: (2026)

Editorial: Risk of Incident Type 2 Diabetes and Prediabetes in Patients With Direct Acting Antiviral‐Induced Cure of Hepatitis C Virus Infection—Authors' Reply
di: Yu‐Ping Chang, et al.
Pubblicazione: (2025)

Diagnosis and non‐invasive assessment of MASLD in type 2 diabetes and obesity
di: Wah‐Kheong Chan, et al.
Pubblicazione: (2024)

Letter: Post‐HCV Cure, Precision Assessment of Liver Stiffness and Diabetes Risk in Maternal Populations—A Critical Research Need
di: Zihe Guan, et al.
Pubblicazione: (2025)

Editorial: Risk of Incident Type 2 Diabetes and Prediabetes in Patients With Direct Acting Antiviral‐Induced Cure of Hepatitis C Virus Infection
di: Nobuharu Tamaki, et al.
Pubblicazione: (2025)

Letter on ‘Unveiling Drug‐Induced Autoimmune‐Like Hepatitis in Autoimmune Hepatitis Patients: A Multicenter Retrospective Study’
di: Muhammad Ibrahim Khalil, et al.
Pubblicazione: (2025)